MedTrace Logo

Effect of Camel Milk on Chronic Hepatitis C

NCT02216045 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2016-07-29

No results posted yet for this study

Summary

Camel milk as the new modality for treatment of chronic hepatitis C. The purpose of this study is to evaluate effectiveness and safety of camel milk in combination with Peginterferon Alfa-2a and Ribavirin in genotype 2,3 chronic hepatitis C virus .

Conditions

  • Chronic Hepatitis C

Interventions

DRUG

Peginterferon, Ribavirin, camel milk

Peginterferon One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks. Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks . camel milk 250 ml of raw camel milk will be consumed in 10 minutes orally twice daily for 12 weeks.

DRUG

Peginterferon, Ribavirin

Peginterferon (PegIFNα-2a) One subcutaneous injection containing 0.5 ml solution with180 mcg PegIFNα-2a per week for 12 weeks. Ribavirin (RBV) tablets (body-weight adjusted dose: \< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg) taken orally (by mouth) once daily for for 12 weeks.

Sponsors & Collaborators

  • Mashhad University of Medical Sciences

    lead OTHER

Principal Investigators

  • Seyyd Musa Al-Reza Hosseini, professor.As · Ghaem Gastrointestinal Clinic

  • Mehdi Yousefi, MD.Phd · Faculty of Traditional Medicine Clinic

  • Mohammadreza Noras, Phd student · Faculty of Traditional Medicine Clinic

  • Ali Taghipour, MD.Phd · MUMS Faculty of Health Sciences

  • Said Zibae, MD.Phd · Razi vaccine and serum Research Institue of Mashhd

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-06-30
Primary Completion
2015-02-28
Completion
2015-02-28

Countries

  • Iran

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02216045 on ClinicalTrials.gov